ERBB2 and breast cancer: Using an unbiased global transcriptome and proteomic analysis of HER2-positive breast-cancer cells, we propose a new model in which acquired resistance to trastuzumab may be mediated by the increased activity of the YAP1/TEAD1-2 complex.